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BACKGROUND: Allowable total error (TEa) goals for he-
moglobin (Hb) A1c require minimal assay imprecision
and bias and implementation of a robust QC monitor-
ing program. Here, we compare the combined influ-
ence on the risk of reporting unreliable results of TEa
goals, a routine QC practice, and assay performance
characteristics of 6 Hb A1c instruments across 4 aca-
demic medical centers.
METHODS: The CLSI protocols EP-5 and EP-9 were ap-
plied to investigate Hb A1c result imprecision and bias
on the Variant II Turbo and Variant II (Bio-Rad), G8
(Tosoh), Capillarys 2 Flex Piercing (Sebia), COBAS In-
tegra 800 (Roche), and DCA Vantage (Siemens).
Patient-weighted  values and the risk of reporting un-
reliable Hb A1c results were determined for each assay
at TEa specifications of 5%, 6%, and 7%.
RESULTS: A large range of patient-weighted  values span-
ning 0.5 orders of magnitude at a 6% TEa was observed.
Although imprecision for all instruments was 3%, bias
impacted the majority of the  changes observed. Esti-
mates for reporting unreliable results varied almost 500-
fold based on analytical performance alone.
CONCLUSIONS: Considerable differences in the probability
of reporting unreliable Hb A1c results between different
NGSP (formerly the National Glycohemoglobin Stan-
dardization Program)-certified platforms were observed.
At a 6% TEa, our study indicates all but the Capillarys 2
Flex Piercing requires that the maximum affordable QC
be run. Risk estimates for individual laboratories’ Hb A1c
methods can be used to assess QC practices and residual
risk of an unreliable Hb A1c result.
© 2014 American Association for Clinical Chemistry
Laboratory QC procedures are implemented to detect,
reduce, and correct deficiencies in the testing process,
with the goal of quickly identifying important errors
before patient results are released (1 ). Historically, sev-
eral options have been available for meeting CLIA QC
requirements for nonwaived testing. The traditional
approach requires that 2 levels of external QC be run
each day of testing. As manufacturers, large reference
laboratories, and hospital laboratories began collecting
QC data, they noted that some test systems rarely failed
QC and questioned the frequency at which external QC
was required. In response, CLIA developed the Equiv-
alent QC option, which reduced the number of exter-
nal QC tests required for eligible methods. This Equiv-
alent QC option will be discontinued in 2016. Recently,
the Centers for Medicare and Medicaid Services an-
nounced a new type of QC plan, the Individualized QC
Plan (IQCP),7 beginning January 2014, that allows lab-
oratories to utilize risk management strategies to de-
sign a QC program. Laboratories will be able to choose
either the traditional approach of testing 2 levels of QC
per assay, per day of patient testing, or they may elect to
develop the newly introduced IQCP, which determines
analytical QC frequency by utilizing risk management
principles.
A risk assessment can be performed to determine if
the current QC practice is adequate or requires revision
(2 ). Currently there is minimal guidance available re-
garding how laboratories may quantitatively estimate
risk to optimize analytical QC criteria appropriate for
an IQCP (2 ). For the laboratory, risk is related to the
chance of producing and reporting unreliable patient
results, which are defined as results containing mea-
surement errors that exceed an allowable total error
(TEa) specification. Evaluation of analytical perfor-
mance characteristics, assay requirements,  metrics,
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and statistical QC plans is one way to estimate risk dur-
ing the analytical phase of testing.
The expected number of unreliable patient results
reported when an assay is out of control is a useful
metric for characterizing a laboratory’s QC strategy in
relation to its analytical performance capabilities.
When an out-of-control condition occurs in the labo-
ratory, the percentage of unreliable patient results pro-
duced while the out-of-control condition exists will
differ from the in-control percentage of unreliable re-
sults. The number of unreliable patient results pro-
duced because of an out-of-control condition will de-
pend on the change in percentage of unreliable results
due to the out-of-control condition and the number of
patient samples examined before the laboratory’s QC
procedures detect the out-of-control condition.
Hemoglobin (Hb) A1c is an ideal assay to pilot risk
assessment of reporting unreliable patient results be-
cause (a) the majority of manufactured Hb A1c assays
in the US are certified by the NGSP (formerly the Na-
tional Glycohemoglobin Standardization Program)
with stringent analytical performance requirements,
(b) multiple testing methods and technologies are
available and used in laboratory and/or point-of-care
(POC) settings, and (c) there is considerable knowl-
edge about the clinical impact of test results. Further,
the prevalence of diabetes mellitus and prediabetes is
increasing around the world and may climb to 50% of
the population in the US by 2020 (3 ). Given that cur-
rent guidelines recommend the use of Hb A1c for the
diagnosis and monitoring of diabetes (4 ), laboratories
may see substantial increases in the volume of Hb A1c
orders.
Currently all Hb A1c assay manufacturers stan-
dardize to the NGSP Reference Method (or technically
NGSP Designated Comparison Method) (5 ). In 2013,
the College of American Pathologists (CAP) profi-
ciency testing acceptance limit decreased to 6%,
leading laboratories to closely scrutinize their Hb A1c
assay performance characteristics and QC practices.
There is, however, limited information available re-
garding the risk of reporting erroneous Hb A1c results
when using NGSP-certified methods. Although the
CAP GH2 proficiency testing survey highlights the ac-
curacy and variation within and between Hb A1c assays,
less is known about how commonly recommended
routine QC practices and assay performance affect the
reliability of an Hb A1c result even when these assays
pass proficiency testing.
The aim of this study was to evaluate the risk of
reporting unreliable Hb A1c results when using cur-
rently available NGSP-certified Hb A1c methods. Six
different Hb A1c assays across 4 academic medical cen-
ters were evaluated using assay performance character-
istics according to CLSI protocols. In the new era of
risk-based QC plans, this provides one example of
quantitative risk estimates that can guide QC strategies
appropriate for an IQCP.
Materials and Methods
Hb A1C ASSAYS
Hb A1c was measured on 6 different analyzers across 4
academic medical centers. These included the Variant
II Turbo (Bio-Rad), Variant II (Bio-Rad), and Tosoh
G8 (Tosoh Bioscience), which are based on ion-
exchange HPLC; the Capillarys 2 Flex Piercing (Sebia),
which is based on capillary electrophoresis; the COBAS
Integra 800 (Roche Diagnostics), which is based on ag-
glutination immunoassay; and DCA Vantage (Sie-
mens), which is based on immunoassay. Two different
DCA Vantage instruments using 2 different lots of cal-
ibrator were evaluated. The Dimension ExL (Siemens)
was also evaluated in this study. However, while this
manuscript was in the review process, the manufac-
turer withdrew from the market the reagent lot that was
evaluated. Therefore, these data have been excluded
from the study.
All assays tested were NGSP certified as of Septem-
ber 2012.
NGSP SAMPLES
Forty NGSP secondary reference laboratory (SRL) tar-
get value–assigned samples (Dr. Randie Little, Univer-
sity of Missouri, performed testing and provided sam-
ples for this study for a fee; NGSP SRL) were sent to
each laboratory and stored at 80 °C until analysis.
PRECISION AND BIAS STUDIES
Precision for each assay was determined using the CLSI
EP5-A2 protocol. Respective laboratory Hb A1c QC
materials (both low QC and high QC) were assayed in
duplicate twice per day (morning and afternoon) for a
total of 20 days. Linear regression and bias were deter-
mined according to the CLSI EP9-A2 protocol. Eight of
40 NGSP SRL samples were thawed each day and tested
in duplicate over a period of 5 days.
STATISTICAL ANALYSES
A representative patient distribution of Hb A1c values
was obtained from 1 facility over a 2-week period.
Sigma values [(TEa  %Bias)/CV] for each instrument
were calculated at each Hb A1c concentration and av-
eraged over the observed Hb A1c patient distribution to
obtain patient-weighted  values. Sigma values directly
relate to the predicted probability of producing an un-
reliable patient result. Given a TEa specification and a
procedure’s %Bias and CV, the percentage of patient
results predicted to be unreliable during stable opera-
tion is computed as:
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In-control % unreliable
 100{1  [F(TEa  %Bias/CV)
 F(TEa  %Bias/CV)]},
where F denotes the standard normal cumulative dis-
tribution function.
The expected number of unreliable final patient
results [E(Nuf)] owing to an out-of-control condition
is defined as the predicted number of unreliable results
produced from the inception of an out-of-control con-
dition up to the last acceptable QC evaluation before
the out-of-control condition’s detection. These results
are considered final because they were produced and
reported before an acceptable QC evaluation. E(Nuf)
depends on TEa, the procedure’s %Bias and CV, the
laboratory’s QC rules and frequency of QC evalua-
tions, and the magnitude of the out-of-control condi-
tion. The method for computing the expected number
of unreliable patient results has been described previ-
ously (6 ).
E(Nuf) was evaluated over a range of possible out-of-
control conditions. Systematic error out-of-control con-
ditions that cause a persistent systematic shift in results
proportional to concentration were assessed over a range
of negative and positive shifts spanning 2 multiples of TEa.
The maximum predicted value of E(Nuf) over the range of
out-of-control conditions was used to assess and compare
performance of the different procedures in response to an
out-of-control condition.
For these analyses, TEa was set to 5%, 6%, and 7%
(to encompass the current state of Hb A1c testing
acceptability in terms of current and previous manu-
facturer NGSP certification and proficiency testing
through the CAP), QC rules were set to the 1:2s rule
(with control limits set at mean  2 SD) with 2 QC
levels, and the mean number of Hb A1c examinations
between QC events was set to 100. Computations were
performed using the MATLAB programming language
(The Mathworks, Inc.).
Results
The comparisons of measured Hb A1c values to target
NGSP SRL results across the 6 Hb A1c assays are shown
in Fig. 1 and summarized in Table 1. Based on data
evaluated at 2 QC levels, the Variant II Turbo and Cap-
illarys 2 Flex Piercing showed the smallest overall bias,
and the Tosoh G8 and Integra 800 had the largest bias
(Table 1). The squared correlation for all assays ranged
from 0.989 [DCA Vantage-lot 1] to 0.999 (Variant II
Turbo, Tosoh G8, Capillarys 2 Flex Piercing) (Table 1).
Percentage bias was calculated from the linear regres-
sion relationships over the range of NGSP target value–
assigned Hb A1c levels and found to differ significantly
across assay platforms (Fig. 2). The Integra 800 and
Bio-Rad Variant II showed the highest variability in
percentage bias across the Hb A1c values tested.
Within-laboratory imprecision (CV) ranged from
1.28% for the Tosoh G8 to 2.97% for the Variant II
Turbo when using low Hb A1c QCs (Table 1). At the
high QC level, imprecision ranged from 0.8% for the
Tosoh G8 to 2.65% for the DCA Vantage-lot 1.
A representative distribution of approximately
1500 Hb A1c patient results for 2 weeks was combined
with the analytical performance characteristics of each
assay shown in Table 1. Together they were used to
generate patient-weighted  metrics and predicted
probabilities of producing unreliable patient results
(measurement errors exceeding TEa) during stable in-
control operation for each Hb A1c assay at TEa specifi-
cations of 7%, 6% (the current CAP proficiency testing
acceptance limit), and 5% (Table 2).
Assuming a 1:2s QC rule with 2 QCs and a mean of
100 Hb A1c examinations between QC events, the pre-
dicted number of unreliable final patient results ex-
Fig. 1. Hb A1c comparisons to target-assigned NGSP
SRL results.
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pected due to the existence of an out-of-control condi-
tion was computed over a wide range of possible
magnitudes of systematic error out-of-control condi-
tions (Fig. 3). The scales of the y axes in Fig. 3 were set
the same for the E(Nuf) graphs shown to provide a
head-to-head evaluation of each assay’s systematic out-
of-control conditions. The lines of the Capillarys 2 Flex
Piercing (Fig. 3D) and the DCA Vantage-lot 2 (Fig. 3G)
graphs are nearly flat due to these assays’ negligible
predicted number of unreliable final patient results,
E(Nuf), over the wide range of possible magnitudes of
systematic error out-of-control conditions. The maxi-
mum expected number of unreliable final patient re-
sults [Max E(Nuf)] out of 100 events over the range of
out-of-control conditions was determined for each as-
say and each TEa (Table 2).
The 6 assays evaluated in this study reflect a wide
range of performance characteristics. The Integra 800
showed the poorest predicted performance. Using a
TEa specification of 6%, its bias and imprecision were
associated with a patient-weighted  value of only 0.36.
If 100 patient samples were tested between QC events,
39.35% of results would be unreliable while in-control,
and in the worst case, as many as 71 unreliable patient
results (out of 100 results total) could be expected
when an out-of-control event occurs (Table 2). In con-
trast, the Capillarys 2 Flex Piercing assay had impreci-
sion and bias profiles that gave the highest patient-
weighted  at each TEa tested. Only 0.02% of results are
predicted to be unreliable while in-control, and 1 un-
reliable patient result (out of 100 results total) would be
expected even for the worst case out-of-control condi-
tion (Table 2). As the TEa specification is decreased, the
patient-weighted  metrics decrease, with a corre-
sponding increase in the risk of reporting unreliable
patient results.
Discussion
QC plans are commonly generated to monitor stability
of laboratory instruments and methods. More recently,
improvements in instrumentation and assay technol-
ogy have led to a transition from using QC to monitor
instrument failure to using QC to minimize risk and/or
mitigate residual risk of reporting an inaccurate result.
Risk management strategies, popularized years ago in
industry (7 ), have recently been touted as an alterna-
tive to a “one-size-fits-all” QC plan that is common in
many laboratories (8, 9 ).
Table 1. Assay performance characteristics across platforms/sites: imprecision and bias across 2 QC levels.
Assay platform
Low QC High QC
Linear regressionc r2Mean % Biasa % CVb Mean % Bias % CV
Variant II 5.09 4.99 1.43 9.74 2.00 1.33 1.107x  0.834 0.991
Variant II Turbo 5.18 0.08 2.97 10.07 0.10 1.81 0.999x  0.012 0.999
Tosoh G8 5.75 3.99 1.28 9.60 4.98 0.80 1.064x  0.130 0.999
Capillarys 2 5.24 0.33 1.66 7.93 0.01 1.33 0.998x  0.016 0.999
Integra 800 5.61 5.76 2.40 9.90 4.07 1.18 1.014x  0.242 0.997
DCA Vantage-lot 1 5.31 0.34 1.88 10.31 2.72 2.65 1.038x  0.161 0.989
DCA Vantage-lot 2 5.23 0.37 1.93 10.49 1.73 1.81 1.024x  0.109 0.991
a % Bias  100  (observed mean  assigned value)/assigned value.
b Precision calculations follow CLSI EP-5A.
c Linear regression of assay results compared to NGSP results measured on a Tosoh HPLC.
Fig. 2. Percentage bias compared to NGSP results
across a range of Hb A1c concentrations.
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The goal of this study was to investigate the impact
of differences in imprecision and bias for Hb A1c assays
on the ability to meet quality goals in terms of patient
risk when using currently available NGSP-certified as-
says. The improvements in Hb A1c instrumentation per-
formance and standardization to the NGSP prompted
CAP to reduce the recommended TEa from 7% to 6% in
2013, with the suggestion that these limits may be fur-
ther reduced in the future. Thus, a secondary interest of
this study was the impact of varying TEa. A fixed QC
rule (1:2s rule with 2 levels of QC) and frequency of QC
evaluations (every 100 Hb A1c examinations) was as-
sumed for each Hb A1c assay tested to ensure that dif-
ferences in risk were a function of only TEa, %CV, and
%Bias. This is not meant to imply an endorsement of a
particular QC rule or frequency at which QC should be
run.
The overall imprecision and bias are important for
interpretation of Hb A1c results. Currently, an intralabo-
ratory imprecision (% CV) of 2% is recommended
(10). All assays except the Bio-Rad Variant II Turbo
(low QC  2.97% CV), Roche Integra 800 (low QC 
2.4% CV), and Siemens DCA Vantage-lot 1 (high
QC  2.65% CV) met this goal at the 2 clinically rele-
vant Hb A1c levels (low and high) tested. A %Bias of
3 accounts for one-half the allowable limit (6%)
afforded by the CAP Hb A1c proficiency testing pro-
gram. Four assays out of 6 in this study displayed a bias
of 3%, indicating a potential larger role for bias in the
overall assessment of Hb A1c method performance. In
this study, bias was sometimes greater at lower or
higher Hb A1c concentrations (Fig. 2).
Assessment of bias or poor calibration in a timely
fashion is sometimes difficult without instituting addi-
tional checks into routine practice. In addition, targets
of internal QC may be unreliable, and comparisons
that include large numbers of NGSP target value–
assigned samples in routine laboratory operations are
not easily accomplished. One suggestion is that calibra-
tion verification samples (if available through the man-
ufacturer or NGSP) be run alongside QC material after
calibration and/or at some predefined time interval of
routine testing. Additional analysis of smaller sample
sizes of NGSP target value–assigned specimens may
Table 2. Risk analysis for Hb A1c assays at 3 different TEa limits.
Assay platform
Patient-weighted sigma In-control % unreliable Max E(Nuf) out of 100 events
7% TEa 6% TEa 5% TEa 7% TEa 6% TEa 5% TEa 7% TEa 6% TEa 5% TEa
Variant II 2.30 1.57 0.83 10.03 19.63 32.81 34.27 46.66 51.54
Variant II Turbo 2.67 2.29 1.90 1.23 2.96 6.62 5.94 11.00 18.27
Tosoh G8 2.27 1.43 0.59 1.19 7.80 28.53 13.67 49.92 83.60
Capillarys 2 4.56 3.90 3.25 0.00 0.02 0.19 0.12 0.60 2.58
Integra 800 0.85 0.36 0.12 25.51 39.35 55.64 60.11 71.48 74.00
DCA Vantage-lot 1 2.84 2.36 1.88 0.69 1.82 4.50 8.85 18.92 36.28
DCA Vantage-lot 2 3.36 2.84 2.32 0.05 0.29 1.32 2.06 6.30 16.55
Fig. 3. The predicted change in the expected number
of unreliable patient results reported prior to an
accepted QC event, E(Nuf), represented on the y axis
computed over a range of possible out-of-control
conditions [systematic error (SE)] shown on the x axis.
TEa was specified as 6%.
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also be performed and compared within-laboratory or
across-laboratories. Although each of these suggestions
appears valuable, their cost and acceptability would
have to be evaluated by each laboratory.
We used both precision and bias to generate sev-
eral outcome metrics, including patient-weighted 
metrics, in-control percentage unreliable patient re-
sults, and maximum expected number of unreliable
patient results due to an out-of-control condition
[Max E(Nuf)]. Sigma values are directly related to the
predicted probability of producing unreliable patient
results during stable operation, which may be ex-
pressed in terms of defects per million opportunities
(DPMO) (7 ). A 6- method is associated with 3.4
DPMO and is classified as “world class quality.” Patient-
weighted  values are a weighted average of  values
across a spectrum of patient results. We used these be-
cause they are a more accurate reflection of  metrics
for a derived patient population (11 ). Our results dem-
onstrate that there is not only substantial variability in
the metrics across platforms as a result of differing an-
alytical performance, but also a sizeable impact from
adjusting the TEa specification.
At the time of this study, all but 1 Hb A1c assay
(Capillarys 2 Flex Piercing) had proficiency testing data
available through the CAP, and those assays that were
in use for clinical practice at the 4 academic medical
centers at the time of this study all successfully passed
their CAP GH2 surveys, indicating the observed bias
did not affect their ability to pass proficiency testing.
However, note the existence of negative E(Nuf) values
for some of the out-of-control conditions shown in Fig.
3. These reflect situations in which the magnitude and
direction of the out-of-control condition negates the
inherent bias in an assay, thereby reducing the likeli-
hood of measurement errors exceeding TEa compared
to the in-control state.
Interestingly, the 2 different calibrator lots (lot 1
and lot 2) tested for the DCA Vantage point-of-care
assay performed better and demonstrated higher
patient-weighted  values than some of the clinical lab-
oratory Hb A1c assays tested. Although the analytical
performance of this method has already been shown to
be superior to other POC methods (12 ), this is the first
report demonstrating that analytical performance of
the DCA assay alone can lead to a reduction in the
maximum expected number of unreliable patient re-
sults from an out-of-control condition. Although this
method performance superiority was evident for both
calibrator lots, one caveat to this interpretation is that
our assessment did not account for any potential pre-
analytical collection variables at the point-of-care level
that may have affected the potential quality of point-
of-care Hb A1c results.
Westgard QC rules have been available for many
years as a guide for monitoring QC. However, labora-
tories have for the most part failed to optimize their QC
procedures (7 ), opting instead for a one-size-fits-all
2-SD rule. It is important to note that large differences
in analytical performance characteristics were ob-
served based on the total volume of patient samples
analyzed between QC events, indicating that a one-
size-fits-all QC plan is not appropriate. Except for the
Capillarys 2 Flex Piercing, the patient-weighted  met-
ric for all platforms investigated at a TEa of 6% was 3,
indicating that maximum QC (3 levels, 3 times per day)
should be performed to achieve the necessary error de-
tection. For this study, the set amount of patient testing
between QC events was 100. E(Nuf) is proportional to
the number of patient samples tested between QC events.
If the number of patients tested between QC events
changes, the risk of reporting unreliable results may also
change. For example, if the number of Hb A1c patient
samples tested between QC events was set at 10 instead of
100, the max E(Nuf) when using the Roche Integra 800
would be 1 out of 100 (at a TEa of 7%). Conversely, if
you double the number of patient samples between QC
events, E(Nuf) will also double. Exhaustive QC events are
often cost prohibitive and can frequently result in a more
complex mechanism of patient testing. The investigation
of assay performance and potential approaches for its im-
provement may yield a better overall solution. A labora-
tory can alternatively implement different QC designs to
reduce cost (13).
Our results show how analytical characteristics
can be used to assess the risk of reporting an unreliable
result. The model incorporates the 3 types of character-
istics that contribute to patient risk: (a) the perfor-
mance characteristics of the testing method (impreci-
sion and bias), (b) the QC strategy used by the
laboratory [number of QC samples, QC rule(s), and
QC frequency], and (c) the quality required of the ana-
lyte (TEa). Each of these characteristics must be assessed
by the laboratory to claim results are fit for their intended
use. Of these, bias and TEa are characteristics laboratories
likely may have the most difficulty with. However, evalu-
ation can be performed first assuming zero bias and again
at an alternative bias derived from peer group compari-
sons to assess the difference in patient risk implications.
Likewise, if it is unclear what TEa to use, different quality
specifications can be tested before implementation to as-
sess the impact on patient risk.
This study demonstrates the importance of align-
ing the risk of reporting unreliable Hb A1c results with
the instrumentation, assay, and patient volumes of the
individual laboratory. Although currently available
NGSP-certified Hb A1c assays can yield satisfactory re-
sults with external quality assessment programs, such
as proficiency testing, it is important that the limita-
1078 Clinical Chemistry 60:8 (2014)
tions of these assays are well understood by laboratory
medicine professionals.
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